Component
NF-kappaB transcriptional activity in human HUVECs
Experimental species, exposure and limitations are retained on each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Indicaxanthin pretreatment suppressed oxidized-LDL-induced NF-kappaB transcriptional activity in HUVECs.
Experimental context and source evidence
- dose
- Indicaxanthin 5-20 micromolar; human oxidized LDL 100 micrograms/mL
- duration
- 1 h pretreatment followed by 16 h oxidized-LDL exposure
- evidence_access
- Primary open full text, relevant results/methods and PubMed metadata.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Human umbilical vein endothelial cells / HUVECs
- limitations
- Expression rescue does not demonstrate plaque regression or ABCA1 cholesterol-efflux flux. Primary-source metadata check found no correction/retraction link; broader integrity not assessed.
- nutrient_topic
- Dedicated indicaxanthin chapter; original betalain family identity and shared claims preserved. · Indicaxanthin
- organism
- Human umbilical vein endothelial cells / HUVECs
- plain_language
- Indicaxanthin pretreatment suppressed oxidized-LDL-induced NF-kappaB transcriptional activity in HUVECs.
- primary_references
- Indicaxanthin from Opuntia ficus indica (L. Mill) Inhibits Oxidized LDL-Mediated Human Endothelial Cell Dysfunction through Inhibition of NF-κB Activation. (2019). https://pubmed.ncbi.nlm.nih.gov/30911345/ DOI: 10.1155/2019/3457846
- route
- In vitro pretreatment and challenge
- tissue
- Endothelial culture
Indicaxanthin: mechanisms, molecular forms and cross-actor connections (2026-09-20) · lines 338–347
Original AI-assisted curation of thirteen additional primary studies, with twenty-six existing claims from eight studies linked unchanged. Study-specific citations and limitations retained. Not publisher full text. · supports · Human umbilical vein endothelial cells / HUVECs · source_derived_draft · unverified_draft
## indicaxanthin-endothelial-nfkb Indicaxanthin pretreatment suppressed oxidized-LDL-induced NF-kappaB transcriptional activity in HUVECs. Model/species: Human umbilical vein endothelial cells / HUVECs Tissue: Endothelial culture Exposure: Indicaxanthin 5-20 micromolar; human oxidized LDL 100 micrograms/mL Route: In vitro pretreatment and challenge Duration: 1 h pretreatment followed by 16 h oxidized-LDL exposure Limits: Expression rescue does not demonstrate plaque regression or ABCA1 cholesterol-efflux flux. Primary-source metadata check found no correction/retraction link; broader integrity not assessed. Primary reference: Indicaxanthin from Opuntia ficus indica (L. Mill) Inhibits Oxidized LDL-Mediated Human Endothelial Cell Dysfunction through Inhibition of NF-κB Activation. (2019). https://pubmed.ncbi.nlm.nih.gov/30911345/ DOI: 10.1155/2019/3457846 Access: Primary open full text, relevant results/methods and PubMed metadata.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.